Scarica l'app Stockscreener
11.53
1.57%
0.20
Precedente Chiudi:
$11.33
Aprire:
$11.5
Volume 24 ore:
5,235
Relative Volume:
0.08
Capitalizzazione di mercato:
$304.74M
Reddito:
$26.00M
Utile/perdita netta:
$-219.71M
Rapporto P/E:
-0.2315
EPS:
-49.8
Flusso di cassa netto:
$-51.37M
1 W Prestazione:
+2.02%
1M Prestazione:
-13.60%
6M Prestazione:
-39.53%
1 anno Prestazione:
-15.82%
Intervallo 1D:
$11.26
$11.88
Intervallo di 1 settimana:
$10.13
$11.88
Portata 52W:
$8.46
$26.50
Cartesian Therapeutics Inc Stock (RNAC) Company Profile
Nome
Cartesian Therapeutics Inc
Settore
Industria
Telefono
301-348-8698
Indirizzo
7495 NEW HORIZON WAY, FREDERICK
Confronta RNAC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RNAC
Cartesian Therapeutics Inc
|
11.72 | 288.62M | 26.00M | -219.71M | -51.37M | -49.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
393.85 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.26 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
433.50 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
645.45 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
302.50 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Cartesian Therapeutics Inc Stock (RNAC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-09 | Iniziato | Wedbush | Outperform |
| 2024-12-19 | Iniziato | BTIG Research | Buy |
| 2024-08-06 | Iniziato | TD Cowen | Buy |
| 2024-07-02 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-06-04 | Iniziato | Oppenheimer | Outperform |
| 2024-05-24 | Iniziato | Mizuho | Buy |
| 2024-04-23 | Reiterato | H.C. Wainwright | Buy |
| 2024-04-23 | Iniziato | Leerink Partners | Outperform |
| 2023-08-18 | Downgrade | SVB Securities | Outperform → Market Perform |
| 2022-06-14 | Reiterato | Needham | Buy |
| 2022-06-06 | Iniziato | SVB Leerink | Outperform |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-01-26 | Aggiornamento | Mizuho | Neutral → Buy |
| 2020-10-01 | Downgrade | Mizuho | Buy → Neutral |
| 2020-10-01 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2020-06-12 | Downgrade | Stifel | Buy → Hold |
| 2020-04-28 | Iniziato | H.C. Wainwright | Buy |
| 2020-01-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-01-21 | Iniziato | William Blair | Outperform |
| 2018-06-27 | Iniziato | Janney | Buy |
| 2017-03-30 | Reiterato | UBS | Buy |
Mostra tutto
Cartesian Therapeutics Inc Borsa (RNAC) Ultime notizie
Can Cartesian Therapeutics Inc. continue delivering strong returnsPost Earnings Surprise Movers - thegnnews.com
Real time alert setup for Cartesian Therapeutics Inc. performanceProfit Target Planning with Exit Confidence - Newser
Cartesian Therapeutics Reports Positive Q2 2025 Earnings - TipRanks
Relative strength of Cartesian Therapeutics Inc. in sector analysisFree Market Momentum and Signal Alerts - Newser
Multi factor analysis applied to Cartesian Therapeutics Inc.Free AI Based High Gain Watchlist Scanner - Newser
Cartesian Therapeutics Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Cartesian Therapeutics 2025 Q2 Earnings Strong Net Income Amid Revenue Decline - AInvest
Cartesian Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Cartesian Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Cartesian (RNAC) Q2 Revenue Drops 99% - sharewise.com
Cartesian Therapeutics reports second quarter 2025 financial results and provides business update - MarketScreener
Cartesian Therapeutics Inc Reports Q2 2025 EPS of $0.51, Surpassing Estimates, with Revenue at $298,000 - GuruFocus
Cartesian Therapeutics, Inc. SEC 10-Q Report - TradingView
Design Therapeutics, Inc. shares rise 1.26% intraday as Cartesian Therapeutics reports strong clinical trial progress and global expansion. - AInvest
Cartesian Therapeutics Announces New Employment Inducement Grants - The Globe and Mail
Cartesian Therapeutics Grants Inducement Awards to New Employees. - AInvest
Cartesian Therapeutics Announces New Employee Incentive Grants - AInvest
Cartesian Therapeutics Expands Leadership Team with Strategic Stock Options Worth $71,760 - Stock Titan
Zacks.com featured highlights Amazon.com, Alphabet and Meta Platforms - The Globe and Mail
Candlestick Signal Suggests Reversal in Cartesian Therapeutics Inc.Expert Verified Stock Trade Ideas Backed by Data - metal.it
Cartesian Therapeutics Inc. Stock Analysis and ForecastBuild wealth faster with disciplined trading - Jammu Links News
Does Cartesian Therapeutics Inc. stock perform well during market downturnsMaximize returns with smart investment plans - Jammu Links News
What institutional investors are buying Cartesian Therapeutics Inc. stockUnlock powerful investment tools for free - Jammu Links News
What catalysts could drive Cartesian Therapeutics Inc. stock higher in 2025Get timely alerts on top-performing stocks - Jammu Links News
What makes Cartesian Therapeutics Inc. stock price move sharplyHarness the power of proven investment plans - Jammu Links News
When is Cartesian Therapeutics Inc. stock expected to show significant growthCapitalize on market shifts before others do - Jammu Links News
Is Cartesian Therapeutics Inc. stock overvalued or undervaluedExceptional trading results - Jammu Links News
Can momentum traders help lift Cartesian Therapeutics Inc.Predictive Short-Term Market Reversal Alerts - Newser
What are the technical indicators suggesting about Cartesian Therapeutics Inc.Free Stock Forecasts For 2025 - Jammu Links News
Chart overlay techniques for tracking Cartesian Therapeutics Inc.Free Alert Feed for Momentum Based Picks - Newser
How to integrate Cartesian Therapeutics Inc. into portfolio analysis toolsRisk-Managed Trade Alerts for Consistency - Newser
Price action breakdown for Cartesian Therapeutics Inc.Free Fast Entry High Potential Stock Alerts - Newser
Progressive Investment Management Corp Reduces Amazon Holdings - The Globe and Mail
How many analysts rate Cartesian Therapeutics Inc. as a “Buy”Free Stock Target Finder With Proven Results - Jammu Links News
Technical signs of recovery in Cartesian Therapeutics Inc.Fast Return Equity Forecast With Logic - Newser
How Cartesian Therapeutics Inc. stock performs during market volatilityFree Optimized Watchlist With Daily Adjustments - Newser
Myasthenia Gravis Market Growth to Accelerate in Forecast - openPR.com
Cartesian Therapeutics Inc. Moves Into Overbought Range Analysts CautiousBuy Alerts With Low Risk Confirmation Noted - metal.it
Why Cartesian Therapeutics Inc. stock attracts strong analyst attentionAlpha Stock Picks with Chart Confirmation - Newser
How to use a screener to detect Cartesian Therapeutics Inc. breakoutsPortfolio Building Plan and Summary Guide - Newser
New Product Launches: Will They Boost Cartesian Therapeutics Inc. Stock in 2025Entry and Exit Strategy Optimizer Tool Tested - metal.it
Risk vs reward if holding onto Cartesian Therapeutics Inc.Free Momentum Based Equity Trading Plan - Newser
Screener Results Flag Cartesian Therapeutics Inc. as OversoldSecure Return Focused Investment Plan Released - metal.it
Cartesian Therapeutics Inc Azioni (RNAC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Cartesian Therapeutics Inc Azioni (RNAC) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| English Emily | Chief Operations Officer |
Apr 15 '25 |
Option Exercise |
3.30 |
7,500 |
24,750 |
47,726 |
| SPRINGER TIMOTHY A | Director |
Apr 10 '25 |
Buy |
10.47 |
48,595 |
508,751 |
620,175 |
| SPRINGER TIMOTHY A | Director |
Apr 09 '25 |
Buy |
9.43 |
41,782 |
393,947 |
571,580 |
| SPRINGER TIMOTHY A | Director |
Apr 11 '25 |
Buy |
10.77 |
36,338 |
391,455 |
656,513 |
| SPRINGER TIMOTHY A | Director |
Apr 10 '25 |
Buy |
10.47 |
8,575 |
89,773 |
8,637,273 |
| SPRINGER TIMOTHY A | Director |
Apr 09 '25 |
Buy |
9.43 |
7,373 |
69,517 |
8,628,698 |
| SPRINGER TIMOTHY A | Director |
Apr 11 '25 |
Buy |
10.77 |
6,412 |
69,074 |
8,643,685 |
| SPRINGER TIMOTHY A | Director |
Mar 20 '25 |
Buy |
15.59 |
54,889 |
855,593 |
8,621,325 |
| SPRINGER TIMOTHY A | Director |
Mar 19 '25 |
Buy |
14.97 |
20,234 |
302,962 |
8,566,436 |
| SPRINGER TIMOTHY A | Director |
Mar 18 '25 |
Buy |
14.42 |
14,740 |
212,599 |
8,546,202 |
1.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):